Exelixis: Delightful Overseas Cabozantinib News
Ipsen (EPA:IPN) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) provided a positive opinion for Exelixis’ (EXEL) product Cabometyx® (cabozantinib) 20, 40, 60 mg regarding the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma (aRCC).

The CHMP positive opinion will be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU).

Alexandre Lebeaut, Ipsen Executive Vice President . . .